Bavarian Nordic (OTCMKTS:BVNRY) Trading Down 7.4% – Here’s What Happened

Bavarian Nordic (OTCMKTS:BVNRY)’s share price dropped 7.4% during trading on Wednesday . The stock traded as low as $10.50 and last traded at $10.50. 1,212 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 3,289 shares. The stock had previously closed at $11.3440.

Bavarian Nordic Stock Performance

The firm has a market cap of $2.50 billion, a PE ratio of 10.60 and a beta of 1.20. The firm’s 50-day moving average price is $9.84 and its two-hundred day moving average price is $9.77.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its earnings results on Friday, August 21st. The company reported $0.46 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 12.06%. The business had revenue of $316.47 million during the quarter.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.